Pharmaceuticals News

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that...

PARIS, FRANCE; CAMBRIDGE, Massachusetts, 25 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de...

PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic...

Eascra Biotech, a nanomedicine startup, has won first place at the TechConnect Bio in Space Innovation Challenge

VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in best-corrected visual acuity (BCVA) and Virtual Reality Visual Test (VRVT),...

– QSIVA ger kliniskt betydelsefull viktnedgång med en väletablerad säkerhetsprofil och erbjuds nu till ett lägre pris i Norden och Polen AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, ett...

– QSIVA tarjoaa kliinisesti merkittävää painonpudotusta hyvin todennetun turvallisuusprofiilin tukemana, ja sitä on nyt saatavilla alennettuun hintaan Pohjoismaissa ja Puolassa AMSTERDAM, March 25,...

— QSIVA tilbyder et væsentligt vægttab, der er klinisk dokumenteret og understøttet af en veletableret sikkerhedsprofil, og er nu tilgængeligt til en reduceret pris i Norden og Polen AMSTERDAM, March...

— QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland AMSTERDAM, March 25, 2026 (GLOBE...

Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study...